Drugs / QLH11811
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05555212 | Oct 2022 → Dec 2024 | non-small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLH11811 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05555212 ↗ |
| Route | Oral | “receive oral single dose of QLH11811” NCT05555212 ↗ |